STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Corcept Therapeutics (CORT) CDO exercises 16,300 options, sells 16,300 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics Chief Development Officer William Guyer reported an options exercise and related sales. On 2026-08-10, he exercised a stock option for 16,300 shares of common stock at an exercise price of $21.65 per share, leaving 110,000 options outstanding under that award, which is fully exercisable. The same day, he acquired 16,300 common shares through the exercise and sold 11,530 shares at a weighted average of $113.1772 (actual prices from $112.80 to $113.75) and 4,770 shares at a weighted average of $114.0371 (actual prices from $113.98 to $114.24). The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024, and his reported holdings include unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.

Positive

  • None.

Negative

  • None.
Insider Guyer William
Role Chief Development Officer
Sold 16,300 shs ($1.85M)
Approx. gross sale proceeds $1.85M
Approx. exercise cost $353K
Approx. pre-tax spread $1.50M
Type Security Shares Price Value
Exercise Stock Option (right to buy) F5 16,300 $0.00 $0.00
Exercise Common Stock F1 16,300 $21.65 $353K
Sale Common Stock F2, F3, F1 11,530 $113.1772 $1.30M
Sale Common Stock F2, F4, F1 4,770 $114.0371 $544K
Holdings After Transaction: Stock Option (right to buy) — 110,000 shares (Direct); Common Stock — 3,985 shares (Direct)
Footnotes (5)
  1. F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5. Fully exercisable.
Options exercised 16,300 shares Stock option (right to buy) exercised on 2026-08-10
Option exercise price $21.65 per share Conversion or exercise price of stock option exercised
Options remaining 110,000 shares Stock options reported as beneficially owned after the exercise
Shares sold (first block) 11,530 shares at $113.1772 Weighted average sale price; individual prices $112.80–$113.75
Shares sold (second block) 4,770 shares at $114.0371 Weighted average sale price; individual prices $113.98–$114.24
10b5-1 plan adoption date November 27, 2024 Plan governing the 2026-08-10 sale transactions
Option expiration date 2031-09-01 Expiration date of the exercised stock option award
Unvested restricted stock 1,599 shares 224 + 498 + 877 shares underlying unvested restricted stock awards
Rule 10b5-1 plan financial
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
restricted stock awards financial
"Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
fully exercisable financial
"Fully exercisable."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Corcept Therapeutics (CORT) executive William Guyer report on this Form 4?
William Guyer, Chief Development Officer, exercised stock options for 16,300 shares at $21.65 and sold 16,300 common shares in market transactions on 2026-08-10, all under a pre-arranged Rule 10b5-1 trading plan.

How many Corcept Therapeutics (CORT) options did William Guyer exercise and what remains?
Guyer exercised 16,300 stock options with a $21.65 exercise price on 2026-08-10. After this transaction, the filing reports he held 110,000 options under that award, which is described as fully exercisable as of the transaction date.

At what prices did William Guyer sell Corcept Therapeutics (CORT) shares?
He sold 11,530 shares at a weighted average $113.1772, with individual prices from $112.80 to $113.75, and 4,770 shares at a weighted average $114.0371, with prices ranging from $113.98 to $114.24 per share.

Was William Guyer’s Corcept Therapeutics (CORT) trading under a Rule 10b5-1 plan?
Yes. A footnote states the reported sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted by William Guyer on November 27, 2024, which was in effect at the time of the 2026-08-10 trades.

What does the Form 4 say about William Guyer’s remaining Corcept Therapeutics (CORT) equity awards?
The filing notes he holds 110,000 options under the exercised grant, fully exercisable until 2031-09-01, and unvested restricted stock awards totaling 1,599 shares that will vest one year after each grant date if service conditions are satisfied.

How were weighted average prices disclosed for William Guyer’s Corcept (CORT) stock sales?
For each sale line, the Form 4 gives a weighted average sale price and states the actual price ranges. Investors can request from Corcept the exact number of shares sold at each individual sale price within those ranges.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Guyer William
(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CALIFORNIA 94065
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Development Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026M16,300A$21.6520,285(1)D
Common Stock08/10/2026S(2)11,530D$113.1772(3)8,755(1)D
Common Stock08/10/2026S(2)4,770D$114.0371(4)3,985(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$21.6508/10/2026M16,300 (5)09/01/2031Common Stock16,300$0.00110,000D
Explanation of Responses:
1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. Fully exercisable.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR